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ABSTRACT
Background The aim of the Dose Reduction or
Discontinuation of Etanercept in Methotrexate-Treated
Rheumatoid Arthritis Patients Who Have Achieved a
Stable Low Disease Activity-State study was to
investigate the effect of etanercept (ETN) dose
maintenance, reduction or withdrawal on patients with
rheumatoid arthritis (RA) who had already achieved
stable low disease activity (LDA) on ETN 50 mg
+methotrexate (MTX).
Methods Patients with RA (n=91) and stable LDA with
ETN 50 mg once weekly (QW)+MTX were included.
After 8 weeks with unchanged treatment, 73 patients
were randomised in a double-blind design to ETN 50 mg
QW+MTX (ETN50), ETN 25 mg QW+MTX (ETN25) or
placebo QW+MTX (PBO) for 48 weeks. Patients who
ﬂared were declared failures and treated with open-label
ETN50 until week 48. The primary outcome was the
proportion of patients on ETN50 versus PBO who were
non-failures after 48 weeks.
Results The proportion of non-failure patients was
signiﬁcantly lower with ETN50 (52%; p=0.007) and
ETN25 (44%; p=0.044) versus PBO (13%). Median time
to failure was signiﬁcantly shorter with PBO (6 weeks)
compared with ETN50 (48 weeks; p=0.001) and ETN25
(36 weeks; p<0.001). The majority of patients who
ﬂared regained LDA with open-label ETN50 quickly.
Adverse events were consistent with the known side
effect proﬁles of these medications.
Conclusions In patients with established RA who have
achieved stable LDA on ETN50+MTX, continuing both is
superior to PBO+MTX. Reduced dose ETN was also
more effective than PBO in maintaining a favourable
response, suggesting that a maintenance strategy with
reduced dose ETN may be possible in a number of
patients with established RA.
Trial registration number NCT00858780.
INTRODUCTION
Rheumatoid arthritis (RA) is one of the most
common autoinﬂammatory diseases, affecting
around 0.5–1% of the adult population in Western
countries.1 2 The disease is chronic, affects women
three times as often as men and is associated with
progressive damage to the bone and cartilage of the
joints, decreases in physical function, reduction in
health-related quality of life and high societal
costs.3–8 Over the past 15 years, treatment has
changed considerably by the introduction of several
antitumour necrosis factor (anti-TNF) biological
therapies, which for many patients have provided
excellent symptomatic relief. The anti-TNF,
etanercept (ETN), is one of the most widely used
and has been shown in several randomised clinical
trials to be effective and comparatively safe.9 10
Klareskog et al11 and Emery et al12 demonstrated
that the combination of ETN with the standard
antirheumatic drug methotrexate (MTX) provides
superior results compared with either medication
alone. Bathon et al13 showed ETN 25 mg twice
weekly monotherapy was superior to a lower dose
of ETN 10 mg twice weekly in patients with active
early RA. Moreover, longitudinal analyses have
shown that a large majority of patients who
achieved a good clinical response with combination
ETN and MTX maintain it with continued treat-
ment.14 However, both from the individual
patient’s standpoint, as well as from a societal per-
spective, it would be advantageous if medication
did not need to be continued indeﬁnitely but could
either be reduced in dose, or even discontinued,
while maintaining a favourable disease activity
state. Only limited data have been published
addressing this possibility. Botsios et al investigated
the effect of a lower dose of ETN (25 mg once
weekly (QW)) on maintaining disease remission
(deﬁned as a disease activity score (DAS) <1.6)
achieved using the standard ETN 25 mg twice-
weekly regimen (study published as a congress
abstract).15 They showed that many of their
patients who received the reduced ETN dose had
not ﬂared during the subsequent year. Similar
uncontrolled observations have also been published
for other anti-TNF agents.16–19 In the majority of
these studies, anti-TNF discontinuation was gener-
ally associated with a ﬂare in disease. Clinical
experience suggests that most patients who reintro-
duce ETN after a temporary interruption regain
disease control. Recently, results from the double-
blinded PRESERVE study showed that low disease
activity (LDA) could be maintained with half the
usual full dose of ETN.20 However, the PRESERVE
study was conducted in patients who would not
necessarily have been treated with an anti-TNF
agent in actual clinical practice.
Here we report the clinical results of a rando-
mised, three-armed, placebo-controlled clinical trial
in patients with RA who had achieved a stable LDA
state with ETN+MTX treatment in regular rheuma-
tology care. In this study, named Dose Reduction or
Discontinuation of Etanercept in Methotrexate-
Treated Rheumatoid Arthritis Patients Who Have
Achieved a Stable Low Disease Activity-State
(DOSERA), one-third of the patients continued with
unchanged (but blinded) medication, one-third
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received a reduced dose of ETN and one-third continued on
MTX alone.
PATIENTS AND METHODS
Adult patients diagnosed with RA were asked to participate if
they had been treated with ETN 50 mg+MTX weekly (in one
single or two divided doses) for at least 14 months; received it
in combination with MTX at a stable dose of 7.5–25 mg/week
for at least 4 months before baseline; and had achieved LDA
(DAS based on a 28-joint assessment (DAS28) ≤3.2, erythrocyte
sedimentation rate method) at the time of screening. Evidence
of LDA at least 11 months prior to the screening visit had to be
documented in either the clinical chart or a clinical registry,
with no contrary data in the interim. Further details about the
sites, inclusion criteria and ethics are provided in the online sup-
plementary text.
Treatment
Patients who entered the study continued on the same medica-
tions, ETN+MTX, for an 8-week run-in period (period 1;
ﬁgure 1A). The MTX dose was kept unchanged throughout the
study. The total weekly dose of ETN was also kept unchanged,
but all patients were provided with the once-weekly 50 mg dose
in the form of the lyophilised product. For most patients, this
entailed a small change from the previously used pre-ﬁlled
syringe and/or the 25 mg twice-weekly dosage.
Patients were assessed clinically at 4-week intervals, including
a 28-joint count, blood tests and patient-reported outcomes.
After 8 weeks, those patients who had maintained a DAS28
≤3.2 during period 1 were randomised to one of three arms
(period 2): ETN 50 mg weekly (unchanged)+MTX (ETN50),
ETN 25 mg weekly (reduced dose)+MTX (ETN25), or placebo
+MTX (PBO). In all three arms, the patients continued MTX,
and other medications, at the same dose.
The patients were assessed every six weeks for 48 weeks in
period 2. If a ﬂare occurred during period 2, the patient was
withdrawn from this phase. Criteria for exiting the double-
blinded phase were (a) DAS28 >5.1; (b) or DAS28 >3.2 and an
increase of ≥1.2 from baseline; (c) or DAS28 >3.2 and an
increase in DAS28 of ≥0.6 from baseline on two consecutive
visits at least 1–3 weeks apart; (d) or disease progression as
determined by either the investigator or disease ﬂare as experi-
enced by the patient (the patient could contact the study site
and be given an evaluation within two weeks and be transferred
into period 3). The latter criterion was introduced to safeguard
the well-being of patients who might experience genuine RA
ﬂares without having increases in DAS28. Patients who discon-
tinued period 2 were designated failures in the primary analysis
(see below), transferred to the third phase (period 3) and
received ETN 50 mg weekly plus MTX. The main purpose of
period 3 was to determine whether any ﬂares occurring during
ETN tapering or withdrawal could be reversed.
Assessments
The primary clinical outcome of this study was the comparison
of the proportion of non-failure patients in the ETN50 group
Figure 1 (A) Schematic description
of the Dose Reduction or
Discontinuation of Etanercept in
Methotrexate-Treated Rheumatoid
Arthritis Patients Who Have Achieved a
Stable Low Disease Activity-State
study. (B) Patient disposition.
ETN, etanercept; MTX, methotrexate;
PBO, placebo; QW, once weekly;
R, Randomise.
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versus the PBO group. Secondary outcomes included compari-
son of non-failure patients between the ETN25 and PBO
groups; time from randomisation to failure in period 2; and
time from failure to LDA/remission (DAS28 ≤3.2) in period
3. Remission was deﬁned as DAS28 ≤2.6. Variables at random-
isation were investigated as predictors of treatment failure (see
online supplementary text). Adverse events (AEs) and serious
AEs were recorded throughout the study.
Statistics
The sample size was estimated on the assumption of a 78% non-
failure rate for the ETN50 group (based on the ﬁndings of a
previous study15). Full details of statistical methodology are pro-
vided in the online supplementary text.
RESULTS
Patient disposition
A total of 106 patients were screened and 91 patients received
at least one dose of ETN in period 1 (ﬁgure 1B). A review of
the prescreening logs revealed that the most common reasons
for patients not proceeding to screening were not being treated
with MTX, patient not interested, patient not suitable and
disease activity too high. Of the 106 patients screened, 33 were
not randomised. Reasons for the screened patients not being
randomised were DAS28 >3.2 during the open-label period
(n=19), patient not able to satisfactorily complete the study
(n=5), no active disease at the time of starting ETN (n=2), no
current treatment with MTX (n=3) and other reasons (n=4).
Thus, a total of 73 patients were available for randomisation
and included in the modiﬁed intention-to-treat population. Of
these patients, 23 were randomised to the ETN50 group, 27 to
the ETN25 group and 23 to the PBO group. Forty-three
patients (59%) failed period 2 and were therefore entered into
period 3. Sixty-six patients (90%) completed periods 2 and 3.
Overall, the mean age was 56.7 (SD 11.0) years, and the
mean disease duration was 13.6 (SD 8.8) years (table 1). The
mean last dose of MTX at screening was 13.9 (SD 5.0) mg/
week. The majority of patients in each treatment group were in
DAS28 remission at randomisation: ETN50 91%, ETN25 78%
and PBO 78%. Although non-signiﬁcant, the ETN25 group had
numerically higher DAS28 and worse radiographic scores at the
time of ETN treatment.
Clinical efﬁcacy
For the primary outcome, the proportion of non-failure
patients was signiﬁcantly greater in the ETN50 group than in
the PBO group: 52% vs 13% at week 48 (p=0.007; ﬁgure 2).
Likewise, the median time to failure was signiﬁcantly longer in
Table 1 Demographics at baseline and disease characteristics at randomisation
Characteristic
ETN50
(n=23)
ETN25
(n=27)
PBO
(n=23)
Total
(n=73)
Age, years 53.8 (12.1) 59.6 (9.2) 56.1 (11.5) 56.7 (11.0)
Female gender, n (%) 17 (74) 18 (67) 16 (70) 51 (70)
Disease duration, years 11.5 (7.3) 16.6 (11.0) 12.3 (6.1) 13.6 (8.8)
Rheumatoid factor positive, n (%) 15 (68) 18 (67) 16 (73) 49 (69)
Prior treatment with DMARDs other than MTX, n (%) 15 (65) 17 (63) 16 (70) 48 (66)
Duration of ETN treatment before study start, years 3.5 (1.4) 3.7 (1.6) 2.9 (1.5) 3.4 (1.5)
DAS28 at start of ETN treatment 4.9 (1.1) 5.2 (1.1) 4.8 (1.1) 5.0 (1.1)
MTX dose 12.1 (4.3) 14.5 (5.0) 15.1 (5.4) 13.9 (5.0)
MTX dose, median (min; max) 10.0 (7.5; 25.0) 15.0 (7.5; 25.0) 15.0 (7.5; 25.0) 15.0 (7.5; 25.0)
Disease characteristics at randomisation
DAS28 remission (≤2.6), n (%) 20 (91) 21 (78) 18 (78) 59 (82)
DAS28 LDA (>2.6 to ≤3.2), n (%) 2 (9) 5 (19)* 5 (22) 12 (17)
DAS28 1.9 (0.6) 1.9 (0.9) 1.9 (0.7) 1.9 (0.7)
Swollen joint count 0.3 (0.8) 0.4 (0.8) 0.2 (0.4) 0.3 (0.7)
Tender joint count 0.2 (0.5) 0.4 (0.8) 0.5 (0.8) 0.4 (0.7)
Pain VAS 15.6 (18.2) 13.0 (10.9) 13.4 (10.1) 13.9 (13.3)
HAQ-DI, median (min; max) 0.25 (0.0; 1.5) 0.38 (0.0; 1.5) 0.13 (0.0; 1.8) 0.25 (0.0; 1.8)
SvdH total score 37.3 (41.6) 69.3 (68.8) 35.4 (30.2) 48.9 (53.0)
SvdH erosion score 25.1 (26.4) 43.6 (39.8) 26.2 (20.9) 32.5 (31.7)
SvdH joint space narrowing score 12.1 (16.9) 25.7 (30.0) 9.2 (10.8) 16.4 (22.6)
Modified intention-to-treat population used. All values are mean (SD) unless otherwise stated.
*n=1 patient had DAS28 >3.2–5.1 at randomisation.
DAS28, disease activity score in 28 joints; DMARD, disease-modifying antirheumatic drug; ETN, etanercept; HAQ-DI, Health Assessment Questionnaire Disability Index; LDA, low disease
activity; MTX, methotrexate; PBO, placebo; SvdH, Sharp van der Heijde; VAS, visual analogue score.
Figure 2 Proportions of non-failure patients in period 2. *OR 7.2
(95% CI, 1.7–29.8), P=0.007 vs. PBO; †OR 1.7 (95% CI, 0.5–5.4),
P=0.362 vs. ETN25; ‡OR 4.2 (95% CI, 1.0–17.0), P=0.044 vs. PBO.
Modiﬁed intention to treat population used. P values calculated using
GEE analysis. ETN, etanercept; MTX, methotrexate; PBO, placebo.
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the ETN50 group than in the PBO group: 48 vs 6 weeks,
p=0.001 (ﬁgure 3A). In the ETN25 group, the proportion of
non-failure patients (44%, p=0.044) was also signiﬁcantly
greater than in the PBO group, and the median time to failure
was signiﬁcantly longer (36 weeks; p<0.001). Two additional
post hoc summaries (which could be considered sensitivity ana-
lyses) were performed. In the ﬁrst, the primary outcome was
summarised only for those patients who at randomisation were
in DAS28-deﬁned remission (DAS28<2.6). In this summary, 3
out of 18 patients (17%) in the PBO group, 11 out of 21
patients (52%) in the ETN25 group and 12 out of 20 patients
(60%) in the ETN50 group were non-failures. In the second,
the patients were categorised according to MTX dose at base-
line: 55 out of 73 patients were on ≤15 mg weekly MTX, and
in these patients the proportions of non-failures in the three
arms were similar to the primary outcome (12/21, 15%; 9/21,
43%; 2/13, 57%); the remaining 18 patients who were on
higher dosages of MTX yielded subgroups too small for sum-
maries to be interpretable.
The majority of patients who had failed during period 2
regained LDA/remission rapidly when retreated with ETN
50 mg+MTX during period 3 (91%; ﬁgure 3B). Median times
from failure to LDA/remission were similar for the ETN50
(6.0 weeks), ETN25 (5.9 weeks) and PBO (3.9 weeks) groups.
Predictors of treatment failure
Results are presented in the online supplementary text and table S1.
Adverse events
AEs were consistent with the patient population and known side
effects of ETN and MTX. During period 1, 27 patients (30%)
experienced 35 AEs, none of which were considered severe and
did not meet the regulatory deﬁnition of serious (see online sup-
plementary table S2). Four of these AEs were considered related
to study treatment; none led to discontinuation or withdrawal.
In the second phase, 43 of the 73 randomised patients (59%)
experienced at least one AE, with a total of 152 AEs reported;
22 patients had AEs considered related to study treatment. In
period 2, two patients (3%) reported a serious AE. One of these
was a patient in the ETN25 group with severe endometritis that
was considered related to the study treatment and led to with-
drawal but was resolved 17 days later. The other serious AE was
back pain, reported in a patient from the ETN50 group, which
was resolved 50 days later and not considered related to the
study treatment. Similar rates of AEs were observed between the
active treatment groups in periods 2 and 3. In period 3, one
patient (2%) experienced pyrexia, a serious AE considered
related to the study treatment that was resolved 18 days later.
No deaths occurred during the course of the study. Additional
safety results are provided in the online supplementary text.
DISCUSSION
In this randomised, double-blinded study, we have shown that in
patients with established RA who have achieved stable LDA with
ETN50+MTX continuation of such treatment to maintain
response is superior to PBO+MTX. In addition, maintenance
treatment with the reduced dose ETN was also more effective
than PBO. These results support those observed in
PRESERVE.20 In the countries where this study was performed,
the treatment combination of ETN+MTX typically requires
moderate or severe RA disease activity and failure to respond to
at least one, but usually several, conventional antirheumatic
agent. Thus, our patient population represents more severe and
refractory disease, in contrast to the moderate disease activity
population in PRESERVE.
While only a small majority of patients with sustained dose
ETN and fewer with reduced dose ETN maintained LDA for
48 weeks, this study still demonstrates that in patients with
established RA who achieved LDA on ETN+MTX discontinu-
ing the maintenance treatment with ETN is associated with a
much higher risk of disease ﬂare than continued treatment.
Failure in this study was deﬁned as both an increase in DAS28
by ≥0.6 (minimal clinically important difference based on prior
studies21 22) and an absolute value >3.2 (the cut-off between
low and moderate disease activity), or the investigator’s/patient’s
assessment of the disease. This criterion was chosen to avoid
classing patients as failures when they had either an increase in
their DAS28 but still remained in the LDA state, or had a
change less than the minimal clinically important difference.
However, as a trade-off, we accepted that some patients might
have a smaller increase in the DAS28 but end up having a
DAS28 >3.2 (eg, increasing from DAS28 value 2.9 to 3.3) and
such patients would not be classiﬁed as failures. In order to
avoid the serious ethical problem that patients might truly
experience a ﬂare in disease activity but not be classed as failures
because of limitations inherent in the measurements used (eg,
DAS28 does not include the ankles and feet and does not reﬂect
the grade of inﬂammation in the individual joints), we also spe-
ciﬁcally allowed patients to contact the investigators if they
experienced a ﬂare. This occurred in four patients within each
treatment group, and they were classiﬁed as failures and subse-
quently entered into period 3 of the study.
The secondary outcomes for the ETN25 group must be inter-
preted with caution. ETN25 was shown to be superior to PBO,
whereas the difference between ETN25 and ETN50 was
modest. However, the study was not powered to demonstrate a
difference or equivalence between these two doses and a true
difference cannot be ruled out (a type 2 error). In addition,
baseline DAS28 was numerically higher although non-signiﬁcant
in the ETN25 group, and this may have affected the outcome.
Notwithstanding these limitations, we believe our results are
important for two reasons. First, from a theoretical point of
view, these clinical results represent the ﬁrst controlled demon-
stration that an induction maintenance strategy can be applied
in some patients with established RA for whom the use of
anti-TNF is clinically necessary. Second, from a clinical practice
point of view, these results suggest that in some patients it may
be possible to reduce dosages while maintaining the same
favourable disease state. MTX remained stable throughout;
therefore, any differences in outcomes could not be explained
by changes in the MTX dose.
The primary analysis was the proportion of patients who
were non-failures after 48 weeks, and the results indicated that a
lower-than-expected proportion of patients who continued full-
dose ETN were non-failures. However, in line with expecta-
tions, this proportion was signiﬁcantly greater than in those
who discontinued ETN. Thus, the proportion of patients con-
sidered failures was higher than anticipated. This is particularly
notable in the patients who continued with unchanged therapy
(ETN50) where prior studies and widespread clinical experience
suggest that they would normally maintain the response during
a given time period of 1 year. One possible explanation for this
apparent anomaly is that when patients are observed frequently
(in this study, every six weeks) and with attention to potential
ﬂares, a greater amount of ﬂuctuation in variables such as tender
and swollen joints will be present than in the normal longitu-
dinal follow-up situation, whether in clinical practice or in an
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Figure 3 (A) Kaplan–Meier (KM) plot
of the time from randomisation to
failure in period 2. (B) KM plot
showing time from failure to LDA/
remission in period 3.
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uncontrolled clinical trial. While such ﬂuctuations mostly occur
as random variations, some may have sufﬁcient magnitude to
achieve the threshold for ﬂare as chosen for this study. This
same mechanism may have been responsible for the relatively
large proportion of patients who did not maintain LDA during
period 1.
For this study, we chose to use LDA as the clinical disease
activity state of interest, implicitly indicating that this was desir-
able and sufﬁcient for this patient group. It could be argued,
based, for example, on the treat-to-target guidelines, the
European League Against Rheumatism and American College of
Rheumatology RA treatment recommendations,23–25 that a
patient population in remission (DAS28 ≤2.6, or by an even
more stringent deﬁnition) would be more appropriate. In fact,
59 (82%) patients had a DAS28 ≤2.6 at randomisation.
However, in the population most likely to be treated with ETN
in clinical practice, that is, in patients with established RA, LDA
has also been considered a reasonable treatment goal according
to these treatment guidelines. Similarly, the objective of this
study was to determine whether a favourable disease state
achieved by MTX+ETN can be maintained by MTX or MTX
+ETN at half dose. Although it may be more intuitive to apply
this question to the patient in remission, it can also be asked for
the patient who has achieved LDA and in whom further
improvement is not considered possible.
An important clinical question is whether ETN at 25 mg
weekly can in some patients be ‘as good as’ 50 mg weekly.
While the current trial may provide suggestions in this regard,
the most convincing method to address this issue would be a
non-inferiority randomised clinical trial where patients in a
stable and favourable disease state are randomly assigned to one
of those two dosages. The trial reported here provides data that
may inform such a future study.
ETN is not approved at doses other than 50 mg weekly (in
one single or two divided dosages) for the treatment of adults
with RA. A dose reduction is therefore not supported by the
product label and also entails some practical difﬁculties. Various
uncontrolled observational studies have suggested that a pro-
longed treatment interval may be effective for some patients as
maintenance therapy.15 19 While pharmacokinetically these two
options are not entirely equivalent, these experiences suggest
that for some patients a more simpliﬁed ETN treatment regimen
might indeed be feasible. However, in view of the current ﬁnd-
ings and other results, we would not advocate reduction of
medication in a patient with LDA who obviously still has
ongoing disease activity.
A speciﬁc concern with discontinuation studies is the risk that
a ﬂare following discontinuation may not be fully reversible.
A classic study on discontinuation of conventional antirheu-
matics clearly demonstrated that this was the case for such medi-
cations (mostly intramuscular gold salts).26 27 The study
performed by Botsios et al15 suggested that remission or LDA
could be recaptured in some but not all patients. In our study,
91% of patients who were declared failures went on to recap-
ture LDA quickly when resuming full-dose ETN under open-
label conditions, providing a measure of reassurance on this
point. The remaining 9% of patients were censored, meaning
that at week 48 they had yet to return to LDA/remission. This
could have been due to the patients not being in period 3 long
enough to reach LDA/remission.
Anti-TNF agents are considerably more expensive than con-
ventional antirheumatic drugs, and as a class have exerted con-
siderable pressures on medication budgets, whether at the
individual, health insurance or national health plan levels. The
ﬁnding that a reduced dosage of an anti-TNF agent could be
effective as maintenance therapy is, if conﬁrmed, important
from a pharmacoeconomic point of view. However, a full assess-
ment of this possibility would require considerably more robust
data in a larger population on the full clinical as well as radio-
graphic effects, both short term and long term, of such therapy.
Moreover, it is not possible to know whether these data would
apply equally to other anti-TNF agents.
The main strengths of this study are the double-blinded ran-
domised design of period 2 and a strict adherence to the proto-
col ensured through 100% monitoring. The study also examines
a question of considerable theoretical and practical importance.
The main weakness of the study is its limited size and associated
wide CIs. This results in uncertainty regarding the comparison
of the clinical efﬁcacies of full-dose and reduced dose ETN
continuation.
Other weaknesses include the documentation of stable LDA
prior to study inclusion could have ‘missed’ ﬂares that occurred
between documented points in time. It is for this reason we
chose to include an 8-week run-in period. In addition, we had
limited knowledge of the patients’ disease state prior to the ori-
ginal initiation of ETN therapy.
In summary, patients with established RA who were given
ETN+MTX in actual clinical practice and achieved LDA, con-
tinuation with ETN either at the full dose or at half dose was
signiﬁcantly superior to discontinuation. Patients who ﬂared
were able to recapture response quickly and effectively with
ETN retreatment.
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